Unilife — Shareholder Meeting (December 2011)
43 slides from Unilife's shareholder meeting presentation, Dec 5, 2011
Slide 1: 2011 Annual General Meeting
2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS)
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our mana
Slide 3: Chairman's Welcome
Chairman's Welcome Jim Bosnjak OAM NASDAQ (UNIS) and ASX (UNS)
Slide 4: The Unilife Board of Directors - Alan Shortall
The Unilife Board of Directors Executive Director and CEO since the founding of Unilife in 2002 Alan Shortall
Slide 5: The Unilife Board of Directors - Jeff Carter
The Unilife Board of Directors Non Executive Director since 2006 CFO of Unilife from 2005 - 2009 Chartered accountant with 25 years experience in financial and senior management roles in U.S. and Australia Jeff Carter MApp. BFin
Slide 6: The Unilife Board of Directors - William Galle
The Unilife Board of Directors Non-Executive Director since 2008 Serves on Compensation and Nominating and Corporate Governance Committees More than 30 years experience in development and implementation of business growth and alternative investment strategies William Galle
Slide 7: The Unilife Board of Directors - John Lund
The Unilife Board of Directors Non-Executive Director since 2009 Chair of Audit Committee Advising publicly listed companies on SEC reporting, M&A, and public accounting audit services since 1991 John Lund, CPA
Slide 8: The Unilife Board of Directors - Mary Kate Wold
The Unilife Board of Directors Non-Executive Director since 2010 Chair of the Strategic Partnerships Committee CEO of Church Pension Fund Group Previously SVP of Finance, Tax and Treasury at Wyeth Mary Kate Wold, J.D.
Slide 9: The Unilife Board of Directors - Marc Firestone
The Unilife Board of Directors Non-Executive Director since 2010 Chair of Nominating and Corporate Governance Committee Executive Vide President and General Counsel for Kraft Foods Marc Firestone J.D.
Slide 10: Agenda
Agenda Confirmation of Quorum Resolutions 2011 Achievements and Outlook - Alan Shortall Questions Confirmation of Results Other Business
Slide 11: Confirmation of Quorum
Confirmation of Quorum Unilife's quorum requirement is one-third of outstanding shares being represented either in person or by proxy Unilife has received at least 50% of the total outstanding shares entitled to vote are represented by person or by proxy.
Slide 12: CEO Presentation by Mr. Alan Shortall
CEO Presentation by Mr. Alan Shortall NASDAQ (UNIS) and ASX (UNS)
Slide 13: Our Position
Our Position Redefining the market for advanced drug delivery systems Innovative, differentiated devices that can enable, enhance and extend the commercial success of injectable drugs and vaccines A rich portfolio of device technologies driven by unmet needs Our devices address the specific needs of
Slide 14: State-of-the-art facility in York, PA
State-of-the-art facility in York, PA Annual Highlights
Slide 15: Our Broad Operational Capabilities
Our Broad Operational Capabilities Enabling us to serve as an integrated partner for device innovation
Slide 16: Continued to strengthen world-class team
Continued to strengthen world-class team Annual Highlights Name Title Previous Employment Dr. Ramin Mojdeh COO BD (Pharma Systems & Product Development) Dr. Jack Kelley VP, Strategic Marketing BD, Medtronic Mike Ratigan VP, Commercial Development BD, Stryker Dr. Masoud Samandi VP, R&D BD Todd Smith
Slide 17: Completion of Unifill Syringe Industrialization Program
Completion of Unifill Syringe Industrialization Program Annual Highlights
Slide 18: Commenced Initial Supply of Unifill Syringe
Commenced Initial Supply of Unifill Syringe Annual Highlights
Slide 19: U.S. Rollout of Unitract 1mL syringes
U.S. Rollout of Unitract(r) 1mL syringes Annual Highlights
Slide 20: Diversified portfolio of Advanced Drug Delivery Systems
Diversified portfolio of Advanced Drug Delivery Systems Annual Highlights
Slide 21: Unifill Select
Unifill Select Annual Highlights
Slide 22: Rita Auto-Injector
Rita Auto-Injector Annual Highlights
Slide 23: AutoInfusor
AutoInfusor Annual Highlights
Slide 24: Novel Device for Targeted Organ Delivery
First organ delivery device scheduled to enter into drug clinical trials with pharmaceutical partner in early 2012 Strong financial opportunity with U.S. and international prevalence rates for the target disease state being very high U.S. treatment costs exceeding $30 billion Device helps enable dru
Slide 25: Recent Capital Raising
Recent Capital Raising U.S. institutional investors purchased 8.25 million shares of Unilife common stock at a price of $4.35 per share 1st U.S. offering over-subscribed, strong participation from blue- chip accounts, healthcare dedicated and long-only funds 8.6% discount to UNIS's closing price of
Slide 26: Recent Capital Raising - Benefits
Recent Capital Raising Benefits of stronger cash position and balance sheet include: Strengthens negotiating position as Unilife begins to finalize partnership agreements with pharmaceutical companies Acceleration of R&D pipeline Expand workforce to support continued business growth Broadens and exp
Slide 27: Summary
All key elements of business strategy now in place Commercial rollout of Unifill proceeding exactly to plan Developed significant new pipeline products in direct response to unmet customer needs Discussions with multiple customers across multiple areas Attractive model with long-term contracts and s
Slide 28: Resolutions
Resolutions
Slide 29: Item 1. Election of Directors
Election of Directors Item 1. Item 1.
Slide 30: Item 2. Ratify appointment of KPMG LLP
Item 2. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2012 the fiscal year ending June 30, 2012 the fiscal year ending June 30, 2012 the fiscal year ending June 30, 2012
Slide 31: Item 3. Advisory vote on executive compensation
Item 3. Item 3. To consider and act on an advisory vote regarding the approval of compensation paid to certain executive officers
Slide 32: Item 4. Frequency of advisory compensation vote
Item 4. Item 4. To consider and act on an advisory vote regarding the frequency of stockholder approval of the compensation of certain executive officers
Slide 33: Item 5. Grant of securities to Slavko Bosnjak
Item 5. Item 5. For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of up to 45,000 securities to Slavko James Joseph Bosnjak on the terms set out in the proxy statement * Excludes 4,440,622 shares voted on this proposal as required by ASX rules.
Slide 34: Item 6. Grant of securities to Jeff Carter
Item 6. Item 6. For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of up to 45,000 securities to Jeff Carter on the terms set out in the proxy statement * Excludes 4,440,622 shares voted on this proposal as required by ASX rules.
Slide 35: Item 7. Grant of securities to William Galle
Item 7. Item 7. For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of up to 45,000 securities to William Galle on the terms set out in the proxy statement * Excludes 4,440,622 shares voted on this proposal as required by ASX rules.
Slide 36: Item 8. Grant of securities to John Lund
Item 8. Item 8. For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of up to 45,000 securities to John Lund on the terms set out in the proxy statement * Excludes 4,440,622 shares voted on this proposal as required by ASX rules.
Slide 37: Item 9. Grant of securities to Mary Katherine Wold
Item 9. Item 9. For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of up to 45,000 securities to Mary Katherine Wold on the terms set out in the proxy statement * Excludes 4,440,622 shares voted on this proposal as required by ASX rules.
Slide 38: Item 10. Grant of securities to Marc Firestone
Item 10. Item 10. For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of up to 45,000 securities to Marc Firestone on the terms set out in the proxy statement * Excludes 4,440,622 shares voted on this proposal as required by ASX rules.
Slide 39: Item 11. Grant of securities to Alan D. Shortall
Item 11. Item 11. For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of up to 1,916,000 securities to Alan D. Shortall on the terms set out in the proxy statement * Excludes 4,440,622 shares voted on this proposal as required by ASX rules.
Slide 40: Item 12. Approve 2009 Stock Incentive Plan amendment
Item 12. Item 12. For the purposes of ASX Listing Rule 7.2 (Exception 9) and for all other purposes, to approve the 2009 Stock Incentive Plan, as proposed to be amended * Excludes 4,440,622 shares voted on this proposal as required by ASX rules.
Slide 41: Questions
Questions
Slide 42: Other Business
Other Business
Slide 43: Meeting Close
Meeting Close 43